Raven White Wolf ~ Psychic Channel

Halloween parade for dogs in costumes, New York

About 20 people from the community of Point May, NL, Canada, came together to rescue two pilot whales.

Intervertebral discs serve as the primary shock absorbers of the musculoskeletal system, utilizing their soft, water-binding nuclear cores to distribute mechanical loads during movement. When these structural cushions experience progressive degeneration, they lose their volumetric moisture content and develop structural fissures or tears, which frequently culminates in chronic localized pain. To address this structural decline, an experimental, second-generation biomaterial known as HYDRAFIL has been engineered to fill internal structural voids and re-establish mechanical support directly within the compromised disc. During the initial clinical feasibility evaluation, physicians administered this heated hydrogel via a percutaneous needle directly into the affected lumbar discs. Done under local sedation, the outpatient procedure relies entirely on real-time fluoroscopic X-ray guidance, bypassing the structural trauma associated with traditional open spinal surgeries. In a preliminary cohort of 20 human participants—all of whom suffered from chronic, treatment-resistant lumbar degenerative disc disease—the therapy yielded substantial clinical improvements. Within six months post-injection, average self-reported pain levels dropped approximately 72%, falling from a severe 7.1 down to a mild 2.0 on a standard 10-point visual analog scale, while concurrently restoring significant functional mobility to the patients' daily routines. While this initial human trial offers promising evidence for percutaneous disc augmentation, the findings remain strictly preliminary. Broader, randomized controlled clinical trials are required to verify long-term efficacy, track potential structural degradation of the material, and monitor rare but serious adverse events, such as hydrogel extravasation or subsequent nerve root compression. Although HYDRAFIL holds a Food and Drug Administration (FDA) Breakthrough Device designation to accelerate its ongoing regulatory review, it has not yet achieved formal FDA clearance for widespread clinical use. Furthermore, financial conflict-of-interest disclosures indicate that the study's lead investigator serves as a medical consultant to the commercial entity backing the implant's development. [Clerk-Lamalice, O., Spath, A., Carcary, K., Amirdelfan, K., & Beall, D. P. (2026). Feasibility and Safety of Treatment of Painful Lumbar Degenerative Disc Disease with an Injectable Hydrogel Implant at One-year Follow-up. Pain Physician, 28(S7), S203-S213]